Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose colchicine and coronary plaque progression after PCI
ChiCTR2300067877Phase 4Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Wenzhou Medical University
- Start
- Feb 2023
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of colchicine in coronary arteriosclerosis (2 arms), sponsored by The First Affiliated Hospital of Wenzhou Medical University. Primary endpoint: percent atheroma volume. Planned start Feb 2023; status: not yet recruiting.
02
Drugs
colchicine
03
Conditions
coronary arteriosclerosis
Beyond the preview
Go deeper on ChiCTR2300067877.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300067877.